CN115500391B

CN115500391B - Fatty acid ester composition containing LPLn/OPLn

Info

Publication number: CN115500391B
Application number: CN202211158998.9A
Authority: CN
Inventors: 孙健; 石丹; 李媛媛; 高鹏; 潘健存; 蒋士龙; 石红丽; 张永久
Original assignee: Heilongjiang Feihe Dairy Co Ltd
Current assignee: Heilongjiang Feihe Dairy Co Ltd
Priority date: 2022-09-22
Filing date: 2022-09-22
Publication date: 2023-10-20
Anticipated expiration: 2042-09-22
Also published as: CN115500391A

Abstract

The present invention relates to a fatty acid ester composition comprising OPL triglyceride, OPO triglyceride, OOL triglyceride, OLL triglyceride, and one or both of LPLn triglyceride and OPLn triglyceride, wherein the total content of LPLn triglyceride and OPLn triglyceride is 0.7% to 2.1% based on the total mass of the triglycerides in the composition, and the total content difference of LPLn triglyceride and OPLn triglyceride is 0.25% or less. The composition disclosed by the invention has the advantages of reasonable fatty acid proportion, very similar grease structure to breast milk, easiness in digestion and capability of providing sufficient nutrition to the maximum extent, and can be added into special diet foods such as infusible foods and infant foods such as infant milk powder.

Description

Fatty acid ester composition containing LPLn/OPLn

Technical Field

The invention belongs to the field of foods, and particularly relates to a fatty acid ester composition containing LPLn/OPLn triglyceride, and more particularly relates to a fat composition which is beneficial to digestion and absorption of a human body and foods containing or using the composition, in particular to infant dairy products.

Background

As is well known, breast feeding is the preferred mode and gold standard for infant feeding, and lipids not only provide 40% -50% of the energy required for infant growth, but also are an important component of infant body. The in vivo lipid mass fraction of neonates is about 11%, and the lipid mass fraction will increase to around 25% in the following months. Therefore, research on breast milk fat has been a hotspot in the field of breast milk research, and infant formulas are ideal choices when breast milk is insufficient or breast feeding is not possible for some reasons, and in addition, analogues of breast milk fat components are also prepared into special diets which are easy to digest and absorb, so that the infant formulas are suitable for people with weak gastrointestinal functions.

Milk contains about 4.0% to about 4.5% lipid, wherein Triglyceride (TG) is about 98%, phospholipid is about 1%, and cholesterol ester are about 0.5%. In recent years, the nutritional value and physiological functions of a series of fatty acids in breast milk, such as oleic acid (O), palmitic acid (P), linoleic acid (L) and linolenic acid (Ln) (essential fatty acids), docosahexaenoic acid (DHA) and Arachidonic Acid (AA), etc., have been intensively studied. The specific structure of the breast milk fat is that saturated fatty acids represented by palmitic acid are mainly distributed at Sn-2 position of triglycerides, while unsaturated fatty acids represented by oleic acid are mainly distributed at Sn-1,3 position of triglycerides, and the maximum content of triglycerides in the breast milk fat is 1, 3-dioleoyl-2-palmitic acid triglyceride (OPO), 1-oleic acid-2-palmitic acid-3-linoleic acid triglyceride (OPL), and the like due to this specific fatty acid distribution. It is generally believed that triglycerides of this structure (especially the type and content of the 2-position structure) are intimately involved in digestion, absorption and metabolism of fat by infants. In addition, the human milk lipid contains medium-long chain triacylglycerols (MLCT) in addition to OPO and OPL triglycerides.

At present, the fat sources in infant formulas mainly comprise: the cow milk fat, the vegetable blend oil or the structural grease OPO are mixed for use. Although the lipid content of cow milk and that of breast milk are similar, the fatty acid compositions of cow milk fat and the like are greatly different, and palmitic acid is often distributed on Sn-1 and Sn-3 of triglyceride, namely a POP structure. After POP structural ester enters a human body, free palmitate is formed under the hydrolysis of pancreatic lipase, calcium soap is easily formed by the free palmitate and calcium ions in food, so that loss of calcium and energy is caused, and besides the poor availability, the infant is easily constipation, and the health of the infant is not facilitated.

In addition, the ratio of saturated fatty acid in cow milk is higher than that in breast milk, and the ratio of unsaturated fatty acid and free fatty acid in breast milk is higher than that in cow milk. Although vegetable oils exist mainly in the form of triglycerides in an amount of 95% or more, sn-2 fatty acids are mainly monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids (PUFAs), unlike human milk. Triglycerides of different structures affect digestion, absorption and metabolism in infants. The fatty acid species and the position distribution of triglycerides determine the absorption form of fatty acids, the specificity of pancreatic lipase.

Although there are some studies aimed at producing a milk-substitute fat or fat composition that is as similar as possible to the composition of milk and the fat structure, there is room for further improvement in the fat ratio.

Reference 1 discloses a method for preparing a structural ester substitute of breast milk fat, which takes palm stearin as a raw material, improves the content of Sn-2-palmitic acid through random transesterification, and then utilizes Sn-1,3 specific lipase to catalyze the palm stearin and mixed fatty acid which undergo the random transesterification to prepare the structural ester similar to the breast milk fat, namely the structural ester substitute of breast milk fat which takes OPO as a main component.

Cited document 2 indicates that there is a large difference in the content and the ratio of OPL to OPO in human breast milk of chinese and human breast milk of other countries. Therefore, the proportion and the content of OPO and OPL components in the grease composition are optimized according to the characteristics of Chinese breast milk components.

Reference 3 discloses a medium-long carbon chain triglyceride for breast milk to replace fat and a preparation method thereof. The fish oil rich in OPL/OPO is used as a raw material, MLCT is synthesized through lipase-catalyzed enzymatic transesterification, and breast milk obtained by blending the MLCT with other grease replaces grease, and compared with breast milk grease, the similarity score of major MLCT and trace MLCT is more than 80 minutes, so that the problem of low similarity of the MLCT composition of infant formula milk powder and mother milk fat is solved.

Reference 4 discloses a breast milk-like oil composition, a preparation method and application thereof, wherein the composition comprises the following components, by weight, 11.01% -17.92% of OPO, 11.10% -20.45% of OPL, 0.92% -1.71% of OPL/OPO, 19% -38% of MLCT and 37.53% -52% of CN 52.

Although the above prior art has attempted to prepare a milk creamer fat that is more similar to the milk cream composition by various preparation methods, the research on this is still insufficient and there is still room for further investigation.

Citation literature:

citation 1: CN107751418A

Citation 2: CN112741163A

Citation 3: CN112522330A

Citation 4: CN114431306A

Disclosure of Invention

Problems to be solved by the invention

As mentioned previously, fat compositions similar to the milk fat composition of breast milk have been proposed in the art. It is still to be noted that although the main fat component composition (including the type and content) of breast milk can be determined by existing instruments, it is almost impossible to obtain a completely reproduced fat composition in breast milk by a manual compounding method. Thus, where a discussion is "similar" to breast milk, it is generally referred to that a portion of the components in the fat composition, for example, are similar to those in breast milk. This also includes the meaning of three layers, first, which fat components are selected to be close to breast milk fat, second, how close this is, and third, which fat components are adjusted to be more conveniently directly related to the particular human application.

In particular studies and practices directed to the prior art, the inventors have also found that a portion of the studies directed to breast milk creamer focus on increasing the Sn-2 palmitic acid content. For example: the optimization of the OPO component was focused on in each of cited document 1 and cited document 2. In addition, another part of the research focuses on bringing more fatty acid esters close to breast milk fat by adjustment of the synthetic manner, for example, cited document 3 and cited document 4.

Further, clinical feeding and experimental study show that infant formulas with unreasonable fatty acid composition and unreasonable structure of fat source can provide energy, but can cause problems such as infant constipation, diarrhea, slow weight growth and the like, and further increase the probability of infection and the like. Fatty acids affect infants in two ways, namely, by changing fatty acid components of cell membrane phospholipids, thereby affecting the fluidity and integrity of the membrane, resulting in dysfunction of various organs of the body; secondly, the content of free fatty acid in the body is excessive, and inflammation and the like are caused, which is unfavorable for healthy growth.

The inventors of the present invention considered that the above-mentioned prior art, although making the fatty acid ester composition closer to breast milk cream by optimizing the content of palmitic acid at the Sn-2 position or optimizing the content of triglycerides of a larger variety, could not be made to be completely close to the milk cream component of breast milk, and therefore, although the degree of approaching was declared to be improved in some cases, it was not a completely reasonable arrangement for human absorption, particularly for digestion and absorption by infants. That is, the present study has emphasized that the composition of milk cream is close to that of breast milk, but there is little attention paid to how to improve the digestibility and absorbability of the human body by reasonably configuring the composition of fatty acid esters.

Therefore, in order to solve the above-mentioned drawbacks of the prior art, the present invention aims to provide a fatty acid ester composition which has a reasonable fatty acid ratio and a fat composition close to that of breast milk, has a remarkably improved digestible effect on the human body, particularly on infants, and can provide sufficient nutrition to the maximum extent, and a food or the like containing the same. Namely, the invention balances the relationship between the proximity of the milk cream and the rationality of the fatty acid ester composition.

Solution for solving the problem

Through long-term researches of the inventor, the technical problems can be solved through the following technical scheme:

[1] a fatty acid ester composition, wherein the fatty acid ester comprises OPL triglyceride, OPO triglyceride, OOL triglyceride, and OLL triglyceride; and comprises one or two of LPLn triglyceride and OPLn triglyceride,

wherein, based on the total mass of triglycerides in the composition,

the total content of LPLn triglyceride and OPLn triglyceride is 0.7% -2.1%, and the total content difference of LPLn triglyceride and OPLn triglyceride is below 0.25%.

[2] The composition according to [1], wherein, based on the total mass of triglycerides in the composition,

The content of OPL triglyceride is 15% -22%;

the content of OPO triglyceride is 12% -18%;

the content of the OOL triglyceride is 7.5% -10.5%.

[3] The composition according to [1] or [2], wherein the total content of the LPLn triglyceride and OPLn triglyceride is 0.8% to 2% based on the total mass of the triglycerides in the composition.

[4] The composition according to [3], wherein the content of the OLL triglyceride is 5.5% or more based on the total mass of the triglyceride in the composition.

[5] The composition according to any one of [1] to [4], wherein the composition comprises a vegetable oil comprising rapeseed oil and soybean oil, optionally comprising one or more of sunflower seed oil, olive oil, sesame oil, corn oil, linseed oil, camellia seed oil.

[6] The composition according to [5], wherein the content of the vegetable oil is 13% to 35% by weight based on the total mass of the composition.

[7] The composition according to [5] or [6], wherein the rapeseed oil is contained in an amount of 1% to 10% and the soybean oil is contained in an amount of 12% to 22% based on the total mass of the composition.

[8] A digestible food product, wherein the food product comprises a composition according to any one of [1] to [7], optionally in the form of an emulsion, a powder, a fortifying agent or a dietary supplement.

[9] The food according to [8], wherein the food comprises a liquid, solid or semi-solid type food, such as pasta, beverage, infusible food, baked confectionery or functional nutritional supplement food, and the beverage comprises a dairy type beverage.

[10] An infant milk product, wherein the milk product comprises the composition according to any one of [1] to [7 ].

ADVANTAGEOUS EFFECTS OF INVENTION

Through implementation of the technical scheme, the invention has the following advantages and can obtain the following technical effects:

1) The invention considers the similarity with breast milk fat and the rationality of the arrangement or composition of fatty acid ester aiming at the problem of easy absorption of human body;

2) The fatty acid ester composition provided by the invention is similar to breast milk fat in composition, and the specific structural grease and various vegetable oils act synergistically to achieve reasonable fatty acid ratio;

3) The fatty acid ester composition provided by the invention has definite ingredients, is more beneficial to convenient and accurate compounding, and is also more beneficial to conveniently adding or preparing various foods, in particular special diet, infant formula foods and the like;

4) The fatty acid ester composition provided by the invention has the advantages that all components are in the safe dosage range, so that the fatty acid ester composition can be used for a long time and is suitable for various unspecified people;

5) The fatty acid ester composition provided by the invention can provide sufficient nutrition to the maximum extent, promote the growth of infants, and has the effects of being easy to digest and absorb.

Detailed Description

The following describes the present invention in detail. The following description of the technical features is based on the representative embodiments and specific examples of the present invention, but the present invention is not limited to these embodiments and specific examples. It should be noted that unless otherwise stated:

in the present specification, the numerical range indicated by the term "numerical value a to numerical value B" means a range including the end point numerical value A, B.

In the present specification, a numerical range indicated by "above" or "below" is a numerical range including the present number.

In the present specification, the use of "substantially" or "substantially" means that the standard deviation from the theoretical model or theoretical data is within 3%, preferably 2%, more preferably 1%, and the deviation herein also includes systematic deviation.

In the present specification, the meaning of "can" includes both the meaning of performing a certain process and the meaning of not performing a certain process.

In this specification, the use of "infant" refers to children from 0 to 6 years old.

In this specification, the use of "milk" means a liquid obtained from the mammary gland of a mammal during lactation. The term "milk" should be interpreted broadly and encompasses both raw milk (i.e. liquid obtained directly from the breast) and standardized dairy products (like e.g. skim milk or whole milk), wherein the concentration of milk fat has been reduced relative to the original raw milk.

In this specification, for convenience of expression for fatty acid glycerides, the following characters are used to refer to different kinds of fatty acids:

ca: capric acid (C10:0); la: lauric acid (C12:0); m: myristic acid (C14:0); p: palmitic acid (C16:0); s: stearic acid (C18:0); o: oleic acid (C18:1); l: linoleic acid (C18:2); ln: linolenic acid (C18:3); ARA: eicosatetraenoic acid (C20:4); DHA docosahexaenoic acid (C22:6);

in this specification, for a specific fatty acid ester, a parallel combination of the above characters is used to indicate the kind of fatty acid glyceride, wherein the letter or letter combination in the middle indicates the fatty acid in the 2-position of glycerin. Specific examples are:

OPO is used to represent 1, 3-dioleoyl-2-palmitoyl triglyceride; using OPL representation: 1-oleic acid-2-palmitic acid-3-linoleic acid triglyceride;

in the present specification, "medium chain fatty acid" as used herein refers to fatty acids having a main chain length of 6 to 12 carbon atoms, and "medium chain fatty acid" refers to fatty acids having a main chain length of more than 12 carbon atoms.

The Chinese terms corresponding to the following terms are as follows:

SFAs, saturated fatty acids; MUFAs: monounsaturated fatty acids; PUFAs: polyunsaturated fatty acids; LCFAs: long chain fatty acids; MCFAs: medium chain fatty acids; MLCT: medium-long chain triglycerides.

The random transesterification referred to in the present specification means a reaction of redistributing acyl groups among or in the triglyceride molecules of the fat and oil, and finally, a random distribution of fatty acids in the triglyceride mixture is achieved. The random transesterification reaction may be carried out in the presence of a chemical catalyst. Non-limiting examples of chemical catalysts include one or more of alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, alkoxides. The hydroxide of an alkali or alkaline earth metal may be selected from KOH, naOH, ca (OH) ₂ . The carbonate of an alkali metal may be selected from K ₂ CO ₃ 、Na ₂ CO ₃ . The alkali metal bicarbonate can be selected from KHCO ₃ 、NaHCO ₃ . Alkali metal alkoxides such as sodium methoxide. The amount of the chemical catalyst to be added is not particularly limited, and may be, for example, 0.01 to 1 wt%, for example, 0.1 wt%, based on the total amount of the oils and fats to be added. The random transesterification reaction may also be carried out in the presence of a lipase.

In this specification, the use of "solution" means a uniform system in which a solute is formed in a substantially or substantially dissolved manner under the conditions of the corresponding solvent, pH and concentration.

In the present specification, when referring to "main component" or "main component" such as fatty acid ester, fat or oil, and mixed structural ester, the content of the corresponding component is higher than the content of other components in the system.

In this specification, the use of "optional" or "optional" means that certain substances, components, steps of performing, conditions of applying, etc. may or may not be used.

As used herein, "room temperature" means the indoor ambient temperature of "20 ℃.

In the present specification, unit names used are international standard unit names, and "%" used represent weight or mass% unless otherwise specified.

Reference throughout this specification to "some specific/preferred embodiments," "other specific/preferred embodiments," "an embodiment," and so forth, means that a particular element (e.g., feature, structure, property, and/or characteristic) described in connection with the embodiment is included in at least one embodiment described herein, and may or may not be present in other embodiments. In addition, it is to be understood that the elements may be combined in any suitable manner in the various embodiments.

The invention provides a fatty acid ester composition with optimized fatty acid triglyceride type, structure and content, and the fatty acid ester composition can bring about obviously improved human body absorbability compared with the prior breast milk-like cream by optimizing the fatty acid ester composition, and particularly has good absorbability for infants.

The technical scheme of the invention is mainly completed based on the following findings:

the existing fatty acid ester compositions of milk cream like milk fat are usually more concerned with the content of palmitic acid in Sn-2 position, mainly because the palmitic acid of fat in raw materials based on animal milk (such as cow's milk) is usually in 1 or 3 position of glycerol, and thus the content of palmitic acid in Sn-2 position in the product fat is increased by corresponding means, so that the composition of the product fat can be made closer to that of milk cream. In addition, referring to the table of the detected components of the milk cream components, various fatty acid triglycerides obtained by transesterification are mixed so that the product fat is more closely attached to the milk cream in terms of components. While prior attempts have attempted to make the product fat composition approach that of breast milk cream, it has been almost impossible to obtain a fat product that is the same as the milk cream component, and although it is generally possible to obtain fat of 80% or more close, such fat is not reasonable in terms of human absorbability in practical use (even if no further study has been made specifically for this, it has been generally considered that the human use effect is close as long as the composition is close. Furthermore, on the basis of focusing on the composition close to breast milk, the fatty acid glyceride composition in the fatty acid ester composition is reasonably blended, so that the obtained oil product has the advantage of obviously improving the human body absorbability in practical application.

< first aspect >

In a first aspect of the present invention, there is provided a fatty acid ester composition which achieves an effect of improving human absorbability by adjusting the content of triglycerides such as OPL, OPO, OOL, OLL, LPLn, OPLn in the composition to a reasonable range.

The fatty acid ester composition provided by the invention comprises OPL triglyceride, OPO triglyceride, OOL triglyceride and OLL triglyceride, and one or two of LPLn triglyceride and OPLn triglyceride.

In some specific embodiments, the fatty acid ester compositions provided herein include OPL triglycerides, OPO triglycerides, OOL triglycerides, OLL triglycerides, LPLn triglycerides, and OPLn triglycerides.

In some specific embodiments, the fatty acid ester composition of the present invention has a total content of LPLn triglycerides and OPLn triglycerides of 0.7 to 2.1 mass%, preferably 0.8 to 2 mass%, more preferably 1 to 2 mass%, even more preferably 1.3 to 1.8 mass%, based on the total mass of triglycerides in the composition. The difference in total content between the LPLn triglyceride and the OPLn triglyceride is 0.25 mass% or less, preferably 0.15 mass% or less, and more preferably 0.1 mass% or less. The present invention recognizes that the two contents are close to the above-mentioned fatty acid ester composition, which is presumably advantageous for better absorption by the human body.

In some specific embodiments, the content of OPL triglycerides in the fatty acid ester composition of the invention is 15 to 22% by mass, preferably 16 to 21% by mass, more preferably 16.5 to 20% by mass, based on the total mass of triglycerides in the composition.

In some specific embodiments, the content of OPO triglycerides in the fatty acid ester composition of the invention is 12 to 18 mass%, preferably 14 to 18 mass%, more preferably 15 to 17.5 mass% based on the total mass of triglycerides in the composition.

In some specific embodiments, the content of OOL triglycerides in the fatty acid ester composition of the present invention is 7.5 to 10.5 mass%, preferably 8 to 10.5 mass%, more preferably 8.5 to 10.5 mass%, based on the total mass of triglycerides in the composition.

In some specific embodiments, the fatty acid ester composition of the present invention has an OLL triglyceride content of 5.5 mass% or more, preferably 6.5 mass% or more, more preferably 8.5 mass% or more, even more preferably 9 mass% or more, based on the total mass of triglycerides in the composition. The upper limit of the content of OLL triglycerides is not particularly limited, and may be 15% by mass, preferably 12% by mass, more preferably 10.5% by mass, from the viewpoint of facilitating absorption with the human body.

On the premise of ensuring the content of each triglyceride in the fatty acid ester composition, the components of the fatty acid ester composition are closer to breast milk fat, and can be beneficial to digestion and absorption of human bodies. The source of the various triglycerides is not particularly limited in the present invention.

In some embodiments, the triglycerides in the fatty acid ester compositions of the present invention may be derived from materials including, but not limited to, existing specific types of triglycerides, structured blend esters, vegetable oils, etc., which may be blended to provide the fatty acid ester compositions of the present invention. Typically, the content of triglycerides such as final OPL, OPO, OOL, OLL, LPLn, OPLn can be adjusted by mixing the OPL structural mixed ester, OPO structural mixed ester and MLCT structural mixed ester of a defined composition with vegetable oil, so that the composition of the invention can achieve effects similar to milk fat component of breast milk and also beneficial to digestion and absorption by human body.

(structural Mixed esters)

The structural mixed ester comprises OPO structural mixed ester, OPL structural mixed ester and MLCT structural mixed ester.

Since it is generally difficult to obtain a structural ester of a high purity in a conventional manner (or it is difficult to put it into practical industrial production because of very poor economy), fat products mainly comprising a structural ester of a certain structure are mainly mixed structural esters containing such structural esters.

The method for producing the mixed structural ester is not particularly limited, and the mixed structural ester can be obtained by conducting an esterification reaction between glycerol and a fatty acid in the presence of a catalyst, or by conducting transesterification reaction between a triglyceride and a fatty acid of various conventional sources in the presence of a (specific) catalyst (enzyme). And optionally, the product of the esterification reaction and transesterification reaction may be post-treated by purification or the like to give the final structurally mixed ester product.

In some transesterification methods typical to be cited, all palmitoylated triglycerides (PPP) are used as reaction raw materials, by adding other fatty acids such as oleic acid, linoleic acid, etc., and transesterifying in the presence of a catalyst such as a specific catalytic enzyme to obtain the objective mixed structure ester.

The above-mentioned mixed structural ester may be synthesized by the above method, or may be obtained directly from commercial products.

OPO structured mixed ester

In the present invention, the term "OPO structure mixed ester" refers to a structure mixed ester containing OPO triglyceride as a main component.

OPO triglyceride, i.e. 1, 3-dioleoyl-2-palmitoyl triglyceride, is a structured fat. The molecular structure of the milk fat can be simulated by an enzymatic transesterification technology, so that the 2-bit palmitic acid ratio is close to the breast milk level, and the milk fat has been applied to infant formulas. The special two-position palmitic acid structure can be hydrolyzed into the palmitic acid monoglyceride under the action of pancreatic lipase, can be combined with bile salt in the body to form chylomicron, is easy to be absorbed by human body, thereby improving the absorption and utilization rate of fatty acid by human body, is not easy to form calcium soap during digestion, has the highest OPO ratio in breast milk fat, and can prevent constipation of infants, promote mineral absorption and provide sufficient energy for infants.

In some specific embodiments of the invention, the OPO structured mixed esters may include triglycerides of other structures, such as OPL, OOL, OPP, OLO, OLL, in addition to OPO triglycerides. The type and amount of triglycerides for these other structures is largely dependent on the manner in which the OPO structured mixed esters are prepared.

In some specific embodiments, the content of OPO triglyceride in the OPO structure mixed ester of the present invention is 53 mass% or more, preferably 55 mass% or more, more preferably 58 mass% or more, and still more preferably 60 mass% or more. The upper limit of the content of OPO triglyceride is not particularly limited, and may be 75 mass%, preferably 70 mass%, more preferably 60 mass% from the viewpoint of economy or availability.

In some preferred embodiments, the OPO structure mixed ester comprises, in addition to the above-defined content of OPO triglycerides, 13 to 18 mass%, preferably 14 to 16 mass% of OPL; and/or, 4 to 10 mass%, preferably 5 to 8 mass% of OOL.

In other preferred embodiments of the present invention, the ratio of P (palmitic acid) at the 2-position in the OPO structure mixed ester is more than 65%, preferably 70% or more, more preferably 75% or more, from the viewpoint of the composition close to breast milk fat. The ratio herein refers to the ratio of the 2-position palmitic acid obtained by mixing all palmitic acid bound to glycerin in the ester in the OPO structure.

OPL structured mixed ester

In the present invention, the term "OPL structural mixed ester" refers to a structural mixed ester containing OPL triglyceride as a main component.

OPL triglycerides, i.e. 1-oleic acid-2-palmitic acid-3-linoleic acid triglycerides, which contain oleic acid and are also rich in linoleic acid. Linoleic acid is a well-known essential fatty acid. Linoleic acid is important for reducing blood cholesterol and preventing atherosclerosis. It was found that cholesterol must be bound to linoleic acid before normal operation and metabolism can be performed in vivo. If linoleic acid is absent, cholesterol is combined with saturated fatty acids, metabolic disorder occurs, atherosclerosis is gradually formed on the vascular wall, and cardiovascular and cerebrovascular diseases are caused. In addition, the linoleic acid has important effects on the development of brain and optic nerve of infants, has obvious effects on improving the intelligence of infants and enhancing visual acuity, and simultaneously has the effects of reducing constipation of infants and promoting absorption of palmitic acid and mineral substances.

In some specific embodiments of the invention, the OPL structural mixed ester may comprise triglycerides of other structures than OPL triglycerides, such as LPL, OPO, OOL, OPP, OLO, OLL. The type and amount of triglycerides for these other structures also depend primarily on the manner in which the OPL structured mixed esters are prepared.

In some specific embodiments, the OPL structured blend esters of the invention have an OPL triglyceride content of 40% by mass or more, preferably 45% by mass or more, more preferably 58% by mass or more, and still more preferably 60% by mass or more. The upper limit of the content of OPL triglyceride is not particularly limited, but may be 65 mass%, preferably 63 mass%, more preferably 60 mass% from the viewpoint of economy or availability.

In some preferred embodiments, the OPL structured blend esters comprise, in addition to the OPL triglycerides in the above-defined amounts, from 5 to 15 mass%, preferably from 8 to 12 mass%, of LPL, the presence of an amount of LPL also being advantageous in increasing the proportion of palmitic acid in the 2-position of the triglycerides.

In other preferred embodiments of the present invention, the ratio of P (palmitic acid) at the 2-position in the OPL structured blend ester is greater than 80%, preferably 85% or more, more preferably 90% or more, from the standpoint of approaching the milk fat composition. The ratio herein refers to the ratio of the 2-position palmitic acid obtained by mixing all palmitic acid bound to glycerin in the ester in the OPO structure. In addition, optionally, in the OPL structural blend ester, the total L (linoleic acid) ratio at positions 1 and 3 is more than 80%, preferably 82% or more, more preferably 85% or more. The total ratio herein also refers to the ratio of linoleic acid at positions 1 and 3 obtained based on all linoleic acid bound to glycerol in the OPL structured mixed ester.

MLCT structural mixed ester

In the present invention, the "MLCT structural mixed ester" is a structural mixed ester containing a medium-long chain fatty acid triglyceride as a main component. "MLCT" refers to medium-long chain triglycerides (Middle to Long Chain Triglycerides), which are structural esters having both medium and long chain fatty acids on the glycerol backbone, wherein medium chain fatty acids refer to fatty acids having 6 to 12 carbon atoms and long chain fatty acids refer to fatty acids having more than 12 carbon atoms. MLCT has the characteristics of medium-long chain fatty acid, and has the characteristics of supplying necessary fatty acid, supplying energy rapidly and not causing fat accumulation.

Common MLCTs in breast milk fat are mainly OPLa, LPLa, OPCa, OLaO, OLaL, OMLa, SLaL and SLaO, etc. The structure of the MLCT is similar to that of OPLa, namely, the palmitic acid is positioned at the Sn-2 position, the oleic acid and the lauric acid are positioned at the Sn-1,3 positions of the triglyceride, so that the absorption of the palmitic acid by infants can be enhanced, the calcium loss in the bodies can be reduced, and meanwhile, the medium-chain fatty acid positioned at the Sn-1,3 positions can be rapidly digested and absorbed to provide energy for the infants. Thus, the so-called "MLCT structured mixed esters" of the present invention also include one or more of the fatty acid triglycerides listed above in view of the close proximity to breast milk fat.

In some embodiments of the invention, the content of OPLa triglycerides in the MLCT structured mixed esters is 20 to 25 mass%, more preferably 21 to 24 mass%.

In addition, from the viewpoint of facilitating absorption by the human body, the content of OLaL triglyceride in the MLCT structured mixed ester is preferably 15 to 20 mass%, more preferably 16 to 18 mass%.

Further, in other preferred embodiments, the mixed ester of MLCT structures has a total Ca ratio at positions 1 and 3 of greater than 65%, preferably 70% or more, from the viewpoint of promoting absorption by the human body. The total ratio herein also refers to the ratio of decanoic acid at positions 1 and 3 obtained by mixing all decanoic acids bound to glycerol in the ester in the MLCT structure.

In the present invention, the source of the mixed ester with the MLCT structure is not particularly limited, and in some preferred embodiments, the MLCT with the composition similar to that of the breast milk fat can be synthesized by taking fish oil rich in OPL/OPO as a raw material and performing enzymatic transesterification through lipase catalysis.

(vegetable oil)

In some embodiments of the invention, the fatty acid ester compositions of the invention comprise vegetable oils. Wherein the vegetable oil comprises rapeseed oil and soybean oil, optionally one or more of sunflower seed oil, olive oil, sesame oil, corn oil, linseed oil and camellia seed oil.

In some specific embodiments, the vegetable oil is present in the fatty acid ester composition of the present invention in an amount of from 13% to 35%, preferably from 15% to 33%, more preferably from 20% to 33%, even more preferably from 23% to 33% by weight of the total mass of the composition.

In some preferred embodiments, the rapeseed oil is present in an amount of 1 to 10 mass%, preferably 5 to 10 mass%, more preferably 7 to 10 mass%, based on the total mass of the fatty acid ester composition; the content of the soybean oil is 12 to 22 mass%, preferably 12 to 20 mass%, more preferably 16 to 20 mass%. Further, the fatty acid ester composition of the present invention may optionally further comprise sunflower seed oil in an amount of 5 mass% or less, preferably 1 to 4 mass%, more preferably 2 to 4 mass%, and olive oil in an amount of 2 mass% or less, preferably 0.5 to 2 mass%, more preferably 1 to 2 mass%.

By configuring the vegetable oil, the closeness between the fatty acid ester composition and breast milk can be further improved, and the configuration of various fatty acid triglycerides is more reasonable from the viewpoint of being beneficial to human body absorption.

(fatty acid ester composition)

The fatty acid ester composition of the present invention includes at least the structurally mixed esters and vegetable oils described above. The method of forming the composition is not particularly limited, and the fatty acid composition of the present invention can be obtained by mixing the composition in a mixing method common in the art.

In some embodiments of the present invention, the content of the OPO structured blend ester in the fatty acid ester composition of the present invention is 18 to 30 mass%, more preferably 20 to 24 mass%, based on the total mass of the fatty acid ester composition, in view of the breast milk cream composition and reasonable arrangement for human absorbability, and satisfying the content requirements of each of the above-mentioned triglycerides. The content of the OPL structural mixed ester is 15 to 28% by mass, more preferably 20 to 25% by mass. The content of the MLCT structural mixed ester is 14 to 24 mass%, more preferably 14 to 20 mass%.

In addition, in some preferred embodiments of the present invention, the fatty acid ester composition of the present invention may further satisfy one or more of the following conditions from the viewpoint of further improving the human body absorbability:

the content of OPLa triglyceride is 3.5-5.3 wt%;

The content of the LPLa triglyceride is 1-2% by mass;

the total content of LPCa triglyceride and OPCa triglyceride is 1.2-2.5% by mass;

m at the 2-position of the triglyceride represents more than 65% of the total M entering the triglyceride;

p at the 2-position of the triglyceride accounts for more than 78% of the total P entering the triglyceride;

ca and La at positions 1 and 3 of the triglyceride account for more than 70% of the total Ca and La entering the triglyceride;

o at the 1 and 3 positions of the triglyceride represents more than 85% of the total O entering the triglyceride;

l at positions 1 and 3 of the triglyceride represents more than 75% of the total L entering the triglyceride;

ln in the 1 and 3 positions of the triglyceride accounts for more than 70% of the total Ln entering the triglyceride;

the La, M and P account for 4.0 to 5.8 mass percent, 0.6 to 3.0 mass percent and 17.8 to 22.5 mass percent of the total composition respectively;

o, L, ln the total composition is 30.1 to 39.9 mass%, 22.1 to 29.5 mass%, and 0.3 to 2.4 mass%.

The other components that can be used in the composition of the present invention are not particularly limited, and other edible ingredients, food additives, solvent components, etc. commonly used in the art can be used without impairing the effects of the present invention.

The fatty acid ester composition of the present invention may exist in a liquid state or may exist in a semi-solid state or in a solid state.

Further, the composition of the invention has excellent in vitro digestion hydrolysis efficiency through experimental verification, which proves that the composition of the invention has the advantage of being digestible. In addition, the animal experiment shows that the content of fatty acid and calcium and magnesium in the excrement of the rat eating the composition of the invention show obvious reduction trend, which indicates that the absorption efficiency of fatty acid, calcium and magnesium is higher. It can be used as special diet and infant formula food.

< second aspect >

In a second aspect of the present invention there is provided a food product which is readily digestible to humans, the food product comprising or using the fatty acid ester composition described in the first aspect of the present invention. The form of the food is not particularly limited, and the fatty acid ester composition of the present invention may be used in the form of emulsion, powder, booster or dietary supplement in preparing the food.

For the food products of the present invention, in some preferred embodiments, particular special meal foods in liquid, semi-solid or solid form are suitable for particular populations (certain gastrointestinal dysfunction or infants). Exemplary include: beverages such as pasta and dairy products, infusible foods, baked cakes, functional nutritional supplementary foods, infusible foods, and the like.

The pasta may include staple foods processed or produced from flour-based raw materials as staple foods, minor cereal-based staple foods, etc., specifically, for example, steamed bread-based, cake-based, noodle-based, and stuffing-based staple foods.

The beverage is not particularly limited, and may be a milk product beverage such as a milk tea beverage, milk, yogurt, or the like.

For a flushable food, typically a flushable milk powder product, such as a pediatric milk powder, an adult milk powder, a middle aged and elderly milk powder, etc.

For baked pastries, baked cakes or biscuits based mainly on cream, eggs and baking powder, etc. can be used.

In particular, the fatty acid ester composition provided by the invention is particularly suitable for application to infant milk products (formula milk powder), and it has been found that by reasonably configuring the type and proportion of fatty acid esters, better absorbability is obtained compared with the existing products.

These special dietary foods are not particularly limited and may be used as a nutritional supplement or as a meal replacement, and such foods may include, in addition to the fatty acid ester composition of the present invention, one or more of the following components: proteins, fats, essential carbohydrates, dietary fibers, supplemental elements, vitamins, plant or dietary components, and the like.

Wherein the protein is at least one selected from whey protein powder, soybean protein isolate, whole milk powder, whole egg powder, lactoferrin, bovine coloctrum, amino acid and protein peptide; and the amino acid is at least one selected from L-lysine-L-glutamic acid, L-arginine, L-tryptophan, L-glutamine, taurine, L-valine, L-isoleucine and L-leucine; the protein peptide is one or more selected from soybean oligopeptide, wheat protein peptide, silkworm chrysalis protein peptide, marine fish oligopeptide powder, cola peptide, amino peptide and ovalbumin peptide.

The fat may comprise at least one of saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, DHA, EPA, ARA, phospholipids, more specifically the fat comprises safflower seed oil, walnut oil, peanut oil, soybean oil, argan, olive oil, tea oil, merry go round robinia oil, olive oil, coconut oil, perilla oil, deep sea fish oil, cocoa butter, palm oil, tallow, butter, lard, medium chain triglycerides, lecithin.

The carbohydrate comprises starch or modified starch. The dietary fiber comprises one or more of inulin, konjaku flour, galacto-oligosaccharide, fructo-oligosaccharide, isomalto-oligosaccharide, soybean polysaccharide, cyclodextrin, resistant dextrin and soybean fiber.

The supplemental element is selected from metal ion salts of organic acids, such as one or more of calcium citrate, L-calcium lactate, calcium hydrogen phosphate, potassium gluconate, sodium citrate, ferrous gluconate, potassium iodide, zinc gluconate, sodium selenite, copper gluconate, chromium sulfate, manganese gluconate, and magnesium gluconate.

The vitamins are selected from one or more of vitamin A, beta-carotene, vitamin D3, vitamin E, vitamin K1, vitamin B2, vitamin B6, vitamin B12, vitamin C, pantothenic acid, folic acid, nicotinic acid, choline, inositol, and biotin.

The plant or dietary component comprises one or more of cereal, beans, potatoes, vegetables, algae, nut seeds, fish and shrimp, livestock meat, and fruits.

Examples

Hereinafter, the present invention will be further specifically described by way of specific examples. Unless specifically stated otherwise, the reagents, methods and apparatus employed in the present invention are those conventional in the art.

< raw materials >

In the examples section below, the raw materials used are as follows, unless otherwise indicated.

OPL structure mixed ester (OPL 60%, LPL 10%, 2-position P89%, 3-position L88%);

OPO structure mixed ester (OPO 55%, OPL 15%, OOL 5%, 2-position P84%);

MLCT structural mixed ester (OPLa 22%, OLaL 17%, ca 91% in 3 position);

OPO and OPL are derived from Yihai Jiaril grain and oil industry Co., ltd, and MLCT is derived from Bangilode oil technology Co., ltd.

Vegetable oils (rapeseed oil, soybean oil, sunflower seed oil, corn oil, camellia seed oil) are commercially available.

The above raw materials were mixed according to the following examples and comparative examples to obtain respective fatty acid compositions.

Example 1:

according to the weight ratio, 25 parts of OPL structure mixed fat, 22 parts of OPO structure mixed fat, 24 parts of MLCT structure mixed fat, 10 parts of rapeseed oil, 15 parts of soybean oil and 3 parts of sunflower seed oil are taken and physically stirred and mixed uniformly. See table 1 for its composition.

Example 2:

according to the weight ratio, taking 22 parts of OPL structure mixed fat, 28 parts of OPO structure mixed fat, 21 parts of MLCT structure mixed fat, 6 parts of rapeseed oil, 16 parts of soybean oil, 3 parts of sunflower seed oil, 1 part of corn oil and 3 parts of camellia seed oil, and physically stirring and uniformly mixing. See table 1 for its composition.

Comparative example 1:

by mixing the above structured fat and vegetable oil (rapeseed oil and soybean oil), a mixed fat was obtained, wherein the rapeseed oil was used in an amount of 15 mass% and the soybean oil was used in an amount of 25 mass%. See table 1 for its composition.

Comparative example 2:

by mixing the above structured fat and vegetable oil (rapeseed oil, soybean oil and sunflower seed oil), a mixed fat was obtained, wherein the rapeseed oil was used in an amount of 5 mass% and the soybean oil was used in an amount of 10 mass%. See table 1 for its composition.

Comparative example 3:

by mixing the above structured fat and vegetable oil (rapeseed oil, soybean oil, sunflower seed oil, corn oil, oil tea seed oil), a mixed fat is obtained, wherein the rapeseed oil is used in an amount of 5 mass% and the soybean oil is used in an amount of 16 mass%. See table 1 for its composition.

Control group:

is commercially available infant formula milk powder with common high OPO content.

Sample a (example 1): the concentrated whey protein powder and casein are taken as protein sources, and the whey in breast milk is used for preparing the milk powder: after casein was mixed at a ratio of 6:4, the fatty acid ester composition of example 1 (the addition amount was 27% of the energy supply ratio of the formulation) and other ingredients were added, and after uniform mixing, the mixture was homogenized, sterilized, concentrated, and spray-dried to prepare sample a.

The main technological parameters are as follows: homogenizing under 20MPa; sterilizing (88-90 ℃ for 15 s); spray drying (inlet air temperature 160-180 deg.c and outlet air temperature 85-90 deg.c).

Sample B (example 2): other materials and processes were consistent and the fatty acid ester composition source was example 2.

Sample C (comparative example 1): other materials and processes were consistent, and the fatty acid ester composition source was comparative example 1.

Sample D (comparative example 2): other materials and processes were consistent, and the fatty acid ester composition source was comparative example 2.

Sample E (comparative example 3): other materials and processes were consistent, and the fatty acid ester composition source was comparative example 3.

Sample S1 (control): other materials and processes were consistent, and the source of the fatty acid ester composition was the control group.

Fat was extracted from commercial infant formula (control) by pretreatment, and the fat and fat of examples and comparative and control were subjected to triglyceride content detection using ultra-high performance liquid chromatography tandem quadrupole time of flight mass spectrometry (UPLC-QTOF-MS), the results of which are shown in table 1 below.

TABLE 1

Triglyceride content (%)

Control group

Example 1

Example 2

Comparative example 1

Comparative example 2

Comparative example 3

OPL

4.09％

20.20％

18.80％

24.00％

19.60％

20.60％

OPO

15.00％

14.95％

17.10％

16.00％

18.50％

11.60％

OOL

5.30％

8.50％

8.06％

9.60％

12.00％

6.18％

OLL

0.60％

9.50％

7.64％

3.18％

5.44％

6.86％

LPLn

/

0.45％

0.90％

0.60％

0.21％

1.45％

OPLn

/

0.45％

0.78％

0.90％

0.35％

1.20％

It can be seen that the OPO content in the above examples and comparative examples is similar to that of the commercial products, i.e., the requirement of closely fitting the breast milk composition can be generally satisfied. In addition, the examples and comparative examples further contain LPLn and OPLn, which enrich essential fatty acids (linolenic acid) in the products, compared with the commercial products.

< in vitro simulated digestion hydrolysis Experimental example >

1. Materials and methods

1.1 major reagents

NaCl、HCl、KCl、CaCl ₂ NaOH, gastric lipase, pepsin, bile salts and pancreatin are all derived from Sigma-Aldrich company

1.2 major instrumentation

Magnetic stirring (IKA company RH-A Basic magnetic stirrer), laser nanoparticle analyzer (Malvern company Nano-ZS 90).

1.3 Experimental procedure

(1) Preparing gastric juice: 0.2g of NaCl is weighed, 1.3mL of HCl with the concentration of 1mol/L is added, 80mL of pure water is used for dissolution, 0.1mol/L of HCl is added for regulating the pH value of the solution to 4.0, and finally, the pure water is used for constant volume to 100mL, and the solution is marked as a solution a. Weighing 5mg of gastric lipase and 0.5mg of pepsin, adding 5mL of solution a, and magnetically stirring at room temperature for 10min to obtain simulated gastric fluid.

(2) Preparation of small intestine digestive juice: weighing 8.78g NaCl,0.37g KCl,6.60g CaCl2, dissolving with pure water, adding 0.2mol/L NaOH to adjust the pH value of the solution to 6.5, and finally adopting pure water to fix the volume to 1L, and marking as solution b. Weighing 5mg of bile salt, dissolving 10mg of pancreatin in 10mL of solution b, and magnetically stirring at 37 ℃ for 10min to obtain simulated small intestine digestive juice.

(3) Simulated digestion: weighing 1.35g of the infant formula milk powder prepared above, adding 9mL of pure water, uniformly stirring to dissolve, keeping the infant formula milk powder in a water bath at 37 ℃ for 10min after no lumps are formed; after the pH value is regulated to 6.0, 2.5mL of simulated gastric fluid is added, the mixture is stirred and digested uniformly at 37 ℃ for 0.5h, then the pH value of the digestive fluid digested by the simulated gastric fluid is regulated to 6.5 by using 0.2mol/L NaOH, 10mL of simulated intestinal fluid is added, simulated small intestine digestion is carried out for 2h, 0.1mol/L NaOH solution is continuously added dropwise in the simulated digestion process, the pH value of the system is kept at 6.5, the NaOH amounts consumed in different times are recorded, and the temperature of the whole process is kept at 37 ℃.

1.4 statistical analysis and calculation

Each sample was subjected to at least 3 simulated digestion tests to determine the release rate of free fatty acids during digestion and the particle size change before and after digestion, and the average was taken.

Release rate (%) =100×v×c×m/2M of free fatty acid, where C is concentration of NaOH solution (0.1 mol/L), V is amount of NaOH solution consumed over a certain period of time (mL), M is molar mass of fatty acid ester composition (g/mol), and M is mass of fatty acid ester composition added (g);

the particle size is detected by a laser nanometer particle size analyzer at 25 ℃.

Experimental data are expressed as mean ± standard deviation (mean ± SD), each experiment repeated at least three times independently, plotted using GraphPad Prism 8.00, excel 2018, and R language, statistically analyzed using SPSS 16.0 software, and analyzed by single factor variance (Duncan's multiple range test). P <0.05 represents significant differences.

1.5 experimental results

To evaluate the digestion and absorption of infant formulas to which fatty acid ester compositions of different structures were added, the free fatty acid release rates at different digestion times were measured as shown in tables 2 and 3.

TABLE 2

TABLE 3 Table 3

In the table above, compared with the control group and the comparative example, the free fatty acid release rate of the examples in the stomach at different digestion times is higher, which indicates that the fatty acid ester composition of the examples of the invention has reasonable proportion and is easier to digest and absorb.

Particle sizes at various digestion times were also measured as shown in table 4.

TABLE 4 Table 4

The table shows that the particle size of the free fatty acid of the embodiment is smaller than that of the control group and the comparative example under different digestion time in the small intestine, and the fatty acid ester composition of the embodiment of the invention is proved to be reasonable in proportion and beneficial to digestion and absorption of human intestinal tracts.

< animal experiment >

1. Materials and methods

1.1 Experimental materials

SD rats (animal breeding center of the national academy of military medical science), male, body weight 300.0 g.+ -. 5.0g; .

1.2 Experimental procedure

(1) Rats were randomly divided into 5 groups of 10 rats each. The control group adopts common vegetable mixed grease (sunflower seed oil, coconut oil, linseed oil and rapeseed oil), the test group adopts the composition examples and the comparison examples, the grease feeding is fixed at 10 am (the grease sample is water-bath to 37 ℃ before the test), the frequency is once in two days, and the feeding amount and the feeding time are respectively 20% of daily average energy intake and 6 weeks. Rats were normally fed and drinking water during the test period, and feed intake and rat body weight were recorded.

(2) Rat feces were collected three consecutive days after 6 weeks of feeding, placed in a centrifuge tube, stored in liquid nitrogen, and subjected to fatty acid detection in the subsequent test. The fecal sample is subjected to lipid extraction as required, fatty acid methyl esterification and analysis by a gas phase method. And determining the content of calcium and magnesium ions in the feces by adopting a mass spectrometry method.

To evaluate the absorption of fatty acids, calcium and magnesium during actual digestion, the content of fatty acids, calcium and magnesium in the feces of rats fed with fatty acid ester compositions of different structures was measured as shown in Table 5.

TABLE 5

In the above table, compared with the control group and the comparative example, the fatty acid ester composition of the embodiment of the present invention has lower content of fatty acid, calcium and magnesium in the feces of the rat fed with the fatty acid ester composition, which indicates that the fatty acid ester composition of the embodiment of the present invention has reasonable proportion and is easier to digest and absorb.

Industrial applicability

The composition of the present invention can be industrially prepared and can be applied to foods.

Claims

1. A fatty acid ester composition close to breast milk fat is characterized in that 25 parts of OPL structure mixed fat, 22 parts of OPO structure mixed fat, 24 parts of MLCT structure mixed fat, 10 parts of rapeseed oil, 15 parts of soybean oil and 3 parts of sunflower seed oil are taken according to the weight ratio, and are physically stirred and mixed uniformly to obtain the fatty acid ester composition,

wherein, the OPL content in the OPL structure mixed ester is 60%, the LPL content is 10%, the triglyceride ratio of 2-position P is 89%, and the triglyceride ratio of 3-position L is 88%;

in the OPO structure mixed ester, the OPO content is 55%, the OPL content is 15%, the OOL content is 5%, and the glycerol triester of 2-position P accounts for 84%;

The mixed ester with the MLCT structure contains 22% of OPLa, 17% of OLaL and 91% of triglyceride with Ca at the 3-position;

the OPO and OPL are derived from Yihaijiali grain and oil industry Co., ltd, the MLCT is derived from Bangilod (Xiamen) oil technology Co., ltd,

and, in the fatty acid ester composition:

OPL content 20.20%, OPO content 14.95%, OOL content 8.50%, OLL content 9.50%, LPLn content 0.45% and OPLn content 0.45%.

2. The fatty acid ester composition close to breast milk fat is characterized in that 22 parts of OPL structure mixed fat, 28 parts of OPO structure mixed fat, 21 parts of MLCT structure mixed fat, 6 parts of rapeseed oil, 16 parts of soybean oil, 3 parts of sunflower seed oil, 1 part of corn oil and 3 parts of camellia seed oil are taken according to the weight ratio, and are physically stirred and mixed uniformly to obtain the fatty acid ester composition,

and, in the fatty acid ester composition:

18.80% OPL, 17.10% OPO, 8.06% OOL, 7.64% OLL, 0.90% LPLn and 0.78% OPLn.

3. Infant milk product, characterized in that it comprises a composition according to claim 1 or 2.